BGR Worldwide represents Altimmune, the clinical-stage biopharmaceutical company that is working on a COVID-19 vaccine and a treatment for liver disease triggered by the obesity epidemic.
The publicly traded Gaithersburg, MD-based company last month reported positive results for its single-dose intranasal COVID-19 vaccine candidate that has been under study in collaboration with the University of Alabama at Birmingham.
CEO Vipin Garg announced Sept. 1 that human trials would begin during the fourth-quarter for its treatment for NASH (non-alcoholic fatty liver disease), which is on the rise due to the increase in obesity. Currently, there, there is no treatment for NASH.
BGR founding partner Ed Rogers, a veteran of the Reagan and Bush I White House, leads the Altimmune effort.
Brent Del Monte, co-lead of BGR's science & life sciences group; John Stone, co-lead of the FDA & public health group, and Remy Brim, senior health advisor to Democratic Senators Patty Murray and Elizabeth Warren, round out BGR's Altimmune team.